A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

NCT00056836 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: rhuFab V2 (ranibizumab)

Sponsor

Genentech, Inc.